Skip to content

Agilent Technologies

US · A #452 by market cap Listed 1999
170.38 -4.96 -2.83%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Official SEC filings

Source: SEC EDGAR. Latest available cached filings; filing date is not the financial period end. Index checked: 2026-11-22 04:43 UTC.

FormFiledOriginal document
8-K2026-11-20Read on SEC.gov
8-K2026-09-08Read on SEC.gov
10-Q2026-09-01Read on SEC.gov
8-K2026-08-26Read on SEC.gov
8-K2026-06-25Read on SEC.gov
10-Q2026-06-01Read on SEC.gov
8-K2026-05-27Read on SEC.gov
8-K2026-05-04Read on SEC.gov

SEC annual financial snapshot

Standard US-GAAP facts in 10-K filings, USD. Income and cash flow cover the annual period; balance-sheet amounts are as of period end. These are not quarterly or TTM figures. Latest available filed values may include restatements; reporting periods can differ from other providers. Checked: 2026-11-21 16:51 UTC.

MetricUSDBasisPeriod endFiledSource
Revenue$6.95BAnnual2025-10-312025-12-2210-K
Net income$1.30BAnnual2025-10-312025-12-2210-K
Operating cash flow$1.56BAnnual2025-10-312025-12-2210-K
Total assets$12.73BAs of2025-10-312025-12-2210-K
Total liabilities$5.99BAs of2025-10-312025-12-2210-K
Stockholders’ equity$6.74BAs of2025-10-312025-12-2210-K
Cash and cash equivalents$1.79BAs of2025-10-312025-12-2210-K

✦ Quant Financial Health how this is computed

Good
  • Altman Z-Score is 6.11, above the 3.0 "safe zone" threshold.
  • Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

✦ Quant Revenue Concentration how this is computed

Diversified
  • Agilent CrossLab is the largest reported line at 41.85% of revenue, across 3 reported segments.
  • No single line clears half of revenue; Life Sciences and Diagnostics Markets is next at 39.72%, spreading the business across more than one real driver.

Revenue annual, last 8 years

Latest year +6.73% YoY

Margins

Gross margin
52.43%
Operating margin
21.29%
Net margin
18.75%

Key ratios & quality

PEG uses trailing P/E against the 3-year net income growth rate (1.29%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Revenue 4.91B5.16B5.34B6.32B6.85B6.83B6.51B6.95B
Gross profit 2.68B2.81B2.84B3.41B3.72B3.47B3.54B3.64B
Selling & admin expenses 1.39B1.46B1.50B1.62B1.64B1.63B1.57B1.71B
Research & development 387.00M404.00M495.00M441.00M467.00M481.00M479.00M455.00M
Operating profit 904.00M941.00M846.00M1.35B1.62B1.35B1.49B1.48B
Pretax profit 946.00M919.00M842.00M1.36B1.50B1.34B1.52B1.44B
Tax 630.00M-152.00M123.00M150.00M250.00M99.00M232.00M132.00M
Net profit 316.00M1.07B719.00M1.21B1.25B1.24B1.29B1.30B
Basic EPS 13244445
Diluted EPS 0.973.372.303.944.184.194.434.57

Balance sheet

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Total current assets 3.85B3.19B3.42B3.80B3.78B4.19B3.96B4.59B
Cash & ST investments 2.25B1.38B1.44B1.58B1.05B1.59B1.33B1.79B
Inventory 638.00M679.00M720.00M830.00M1.04B1.03B972.00M1.03B
Total assets 8.54B9.45B9.63B10.71B10.53B10.76B11.85B12.73B
Total current liabilities 1.17B2.08B1.47B1.71B1.86B1.60B1.90B2.35B
Short-term debt --616.00M75.00M--36.00M--45.00M304.00M
Long-term debt 1.80B1.79B2.28B2.73B2.73B2.74B3.35B3.05B
Total liabilities 3,970,000,000.004,704,000,000.004,754,000,000.005,316,000,000.005,227,000,000.004,918,000,000.005,948,000,000.005,986,000,000.00
Total equity 4.57B4.75B4.87B5.39B5.31B5.85B5.90B6.74B
Retained earnings -336.00M-18.00M81.00M348.00M324.00M782.00M750.00M1.39B

Cash flow

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Operating cash flow 1.09B1.02B921.00M1.49B1.31B1.77B1.75B1.56B
Depreciation & amortization 210.00M238.00M308.00M321.00M317.00M271.00M257.00M288.00M
Free cash flow 910.00M865.00M802.00M1.30B1.02B1.47B1.37B1.15B
Dividends paid -191.00M-206.00M-222.00M-236.00M-250.00M-265.00M-274.00M-282.00M
Stock buybacks / issuance -422.00M-723.00M-469.00M-788.00M-1.14B-575.00M-1.15B-425.00M
Ending cash balance 2.25B1.39B1.45B1.49B1.06B1.59B1.33B1.79B

Returns & efficiency

Line item 2018 2019 2020 2021 2022 2023 2024 2025
ROE % 6.7223.0014.9523.5823.4522.2421.9520.62
ROA % 3.7211.907.5411.9011.8111.6511.4010.61
ROIC % 5.2815.5410.8316.7616.2315.4114.5413.91
5-year avg ROE % 10.3312.8514.1516.6618.3421.4421.2422.37
EBIT margin % 20.7819.2317.2322.8023.1920.9924.8422.27
FCF / sales % 18.5216.7515.0220.5114.9121.5721.0916.58
Current ratio 3.291.532.332.222.032.612.091.96
Quick ratio 2.581.111.691.611.321.801.401.40
Debt / assets 21.0625.4724.5025.4926.2925.4128.6226.35
LT debt / equity 39.3937.7246.8750.6451.5246.7956.7145.25
Interest coverage 13.6113.4211.7917.7918.9015.0916.8413.81
Revenue CAGR (3Y) % 6.767.116.088.749.878.571.000.48
Net income CAGR (3Y) % -7.6332.351.6856.455.4019.922.131.29
FCF CAGR (3Y) % 30.029.774.0012.545.6822.491.924.11

Revenue breakdown most recent period

Business

Agilent CrossLab41.85%
Life Sciences and Diagnostics Markets39.72%
Applied Markets18.42%

Quote time 2026-11-20 20:01:22 · For reference only, not investment advice and not tailored to your situation.

Agilent Technologies discussion 0 comments

Add a comment